comparemela.com

Latest Breaking News On - Medilink therapeutics suzhou co - Page 1 : comparemela.com

BioNTech : Annual Financial Statements as of 31 December 2023

Translation from the German language Annual Financial Statements of BioNTech SE, Mainz, December 31, 2023 Translation.

United kingdomUnited statesCity ofMedilink therapeutics suzhou coMainz local courtBiontech biontainer holding gmbBiontech united states holdingInstadeep ltdGerman stock corporation act aktOrganisation for economicDuality biologics suzhou coBiotheus incFinancial statementsFinancial positionSeparate financial statementsAnnual financial statements

BioNTech : Annual financial statements of BioNTech SE as of 31 December 2023

Translation from the German language Annual Financial Statements of BioNTech SE, Mainz, December 31, 2023 Translation.

United kingdomUnited statesCity ofBiontech biontainer holding gmbMainz local courtMedilink therapeutics suzhou coDuality biologics suzhou coBiotheus incGerman stock corporation act aktOrganisation for economicInstadeep ltdBiontech united states holdingFinancial statementsFinancial positionSeparate financial statementsAnnual financial statements

MediLink Therapeutics Announces Strategic Collaboration and Worldwide License Agreement with BioNTech to develop next-generation anti-cancer antibody-drug conjugate

/PRNewswire/ MediLink Therapeutics ("MediLink"), announced today that it has entered into a strategic research collaboration and worldwide license agreement.

United statesMedilink therapeuticsHuman epidermal growth factor receptorMainland chinaHong kong special administrative regionMacau special administrativeAntitrust improvementsLink therapeuticsTumor microenviroment activableMedilink therapeutics suzhou co

MediLink Therapeutics Receives FDA Clearance of IND Application for YL201 Antibody Drug Conjugate Product

/PRNewswire/ MediLink Therapeutics announced that YL201, the first compound based on MediLink s proprietary antibody-drug conjugate (ADC) technology.

Lei yangMicroenviroment activable linkerDrug administrationMedilink therapeutics suzhou co ltdLink therapeuticsInvestigational new drugTumor microenviroment activable linkerMedilink therapeuticsMedilink therapeutics suzhou co

vimarsana © 2020. All Rights Reserved.